Active substance
Procyclidine
- SFDA 4
- US FDA 1
- NHS prices 4
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| KEMADRIN 5MG TABLET | 5 mg | Tablet · Oral use | 100 Tablet Container | SAR 26.95 | Generic · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| KEMADRIN 5MG TABLET | 5 mg | Tablet · Oral use | 100 Tablet Container | SAR 27.00 | Generic · Prescription | ASPEN | Withdrawn by MAH · Not Marketed |
| KEMADRIN INJ 10MG-2ML | 5 mg/ml | Solution · Intravenous use | 5 Ampoule | SAR 30.10 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by MAH · Not Marketed |
| KEMADRIN TABS 5 MG | 5 mg | Tablet · Oral use | 100 Blister | SAR 27.30 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by regulatory authority · Not Marketed |
Indications — CHI Daman Drug Formulary
PARKINSONISM; SCHIZOPHRENIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| KEMADRIN | 5MG; 2MG | tablet · oral | MONARCH PHARMS | Discontinued | 27 Jul 1955 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Procyclidine 10mg/2ml solution for injection ampoules | £72.50 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Procyclidine 2.5mg/5ml oral solution sugar free | £51.17 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Procyclidine 5mg tablets | £1.30 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Procyclidine 5mg/5ml oral solution sugar free | £75.78 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 12 Jul 2018 PRAC signal: Dementia
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.